GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Cyclically Adjusted PS Ratio

Synergy Pharmaceuticals (FRA:S90) Cyclically Adjusted PS Ratio : (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Synergy Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Synergy Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Synergy Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2018 is calculated as:

For example, Synergy Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2018 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2018 (Change)*Current CPI (Sep. 2018)
=0.038/106.5067*106.5067
=0.038

Current CPI (Sep. 2018) = 106.5067.

Synergy Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200812 0.000 88.697 0.000
200903 0.000 89.744 0.000
200906 0.000 91.003 0.000
200909 0.000 91.120 0.000
200912 0.000 91.111 0.000
201003 0.000 91.821 0.000
201006 0.000 91.962 0.000
201009 0.000 92.162 0.000
201012 0.000 92.474 0.000
201103 0.000 94.283 0.000
201106 0.000 95.235 0.000
201109 0.000 95.727 0.000
201112 0.000 95.213 0.000
201203 0.000 96.783 0.000
201206 0.000 96.819 0.000
201209 0.000 97.633 0.000
201212 0.000 96.871 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.009 103.349 0.009
201709 0.019 104.136 0.019
201712 0.034 104.011 0.035
201803 0.028 105.290 0.028
201806 0.042 106.317 0.042
201809 0.038 106.507 0.038

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Synergy Pharmaceuticals  (FRA:S90) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Synergy Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines